Gracell Biotechnologies (Shanghai) Co., Ltd.
2 clinical trials · 2 recruiting · INDUSTRY
Trials by Gracell Biotechnologies (Shanghai) Co., Ltd.
RECRUITINGPhase 1 / Phase 2NCT06235229
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.
Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd.Enrolling: 11010 locations
Multiple Myeloma
RECRUITINGPhase 1NCT06530849
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus
This is a single-arm, open-label, multicenter, phase 1/2 clinical study to assess the safety and efficacy of GC012F Injection in subjects with refractory Systemic Lupus...
Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd.Enrolling: 182 locations
Refractory Systemic Lupus Erythematosus